Quark Pharmaceuticals

** QUARK is conducting A Dose Escalation Trial of the Safety and Pharmacokinetics of a Single Intravenous Injection of I5NP (AKIi-5) in Patients Undergoing Major Cardiovascular Surgery. This study is currently recruiting participants: clinicaltrials.gov

Quark Pharmaceuticals is an evolving pharmaceutical company using rational drug design to develop new therapeutics for unmet medical needs. Our proprietary te...

Modified siRNA in development for neovascular (wet) age-related macular degeneration (AMD), recently licensed to Pfizer. RTP801i-14 is a siRNA drug de...

Modified siRNA in development for acute renal failure (ARF). It inhibits the development of ARF in animals following a single iv injection. AKIi-5 wi...

7/30/2008

Quark Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in DME

Clinical Program Leverages Quark’s RNAi Technology

4/7/2008

Quark Receives FDA Approval of IND For Kidney Transplant

Quark’s second siRNA drug delivered systemically